Abstract T MP114: Hyperlipidemia and Statin Use: Is There an Effect on Mortality Following an Ischemic Stroke?
Background: Prior treatment with stain use is associated with reduced risk of arterial ischemic stroke (AIS) occurrence and recurrence. Recent studies report elevated lipid levels are associated with improved survival in AIS patients. We investigated the association of hyperlipidemia and statin use on all-cause mortality in AIS patients.
Methods: All AIS patients, age ≥ 20 years (n=3898) residing within the Greater Cincinnati/Northern Kentucky region in 2005 and 2010 were included in the analysis. Based on prior medical history of hyperlipidemia or elevated fasting LDL levels during hospitalization (HLD) and statin use at baseline and/or discharge, patients were categorized as follows. Group1: no HLD and no statin use, Group2: HLD and no statin use, Group3: HLD and statin use. Covariates included age, BMI, baseline stroke severity (NIHSS), history of: hypertension, heart disease, diabetes, end-stage renal disease, dementia, prior stroke, and smoking. Multivariable logistic regression was used to estimate the odds of mortality, at 30- and 90-days and 1-, 2- and 3-years post stroke.
Results: There were 22%, 21%, and 56% patients in groups 1, 2, and 3 respectively. Those in groups 2 and 3 were significantly younger, heavier, more likely to be male and have hypertension, diabetes, heart disease, and severe stroke, but less likely to have atrial fibrillation, dementia, and prestroke disability compared to patients in group 1. In unadjusted and adjusted analyses, patients in group 3 showed lower odds of mortality at all the time points compared to patients in groups 1 and 2. Patients in group 2 also showed lower odds of mortality at all the time points compared to patients in group 1 (Table).
Conclusions: A pre-morbid diagnosis of HLD is associated with lower mortality in AIS patients, irrespective of statin use. Statin use appears to be associated with additional improved survival.
Author Disclosures: S. Yeramaneni: None. D. Kleindorfer: None. H. Sucharew: None. K. Alwell: None. C. Moomaw: None. M. Flaherty: None. D. Woo: None. O. Adeoye: None. S. Ferioli: None. F. De Los Rios La Rosa: None. S. Martini: None. J. Mackey: None. P. Khatri: Research Grant; Modest; Dr. Khatri’s Dept of Neurology receives support for her role DSMB member from Biogen, Inc.. Research Grant; Significant; Dr. Khatri’s Dept of Neurology receives support for her roles as: (1) Lead PI of the PRISMS trial from Genentech, Inc and (2) Neurology PI of the THERAPY trial from Penumbra, Inc.. B. Kissela: None. J. Khoury: None.
- © 2015 by American Heart Association, Inc.